Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer survivors. Despite the proven efficacy, the non-adherence rate to therapy is still high. This study is aimed to examine women's challenges related to AET adherence and management. Semi-structured interviews were conducted with six Caucasian and six African American breast cancer survivors who were prescribed for AET. The transcripts of audio-taped interviews were qualitatively analyzed. Key themes were: 1) positive beliefs in AET, 2) uncertainty about long-term adherence, 3) experiences with side effects, 4) forgetting and remembering, 5) other concerns and information needs, 6) potential intervention format, and 7) culturally-coping among African American women. The findings provided insight into women's experiences and beliefs and how these behaviors might influence AET adherence. Although most women in this study took AET as prescribed, many experienced a range of side effects and emotional distress, often without seeking support or help. New models of programs to promote adherence, support symptom management, and ultimately improve survival are critically needed. Developing culturally sensitive interventions for African American women is desirable.
Introduction
Both national and international guidelines have recommended the long-term use of tamoxifen and aromatases inhibitors (AIs) for breast cancer surveillance management over the past few decades 1, 2 , and recently, updated guidelines recommended 10 years of adjuvant endocrine therapy (AET) in women with hormone receptor-positive breast cancer 3 , approximately 75-80% of all breast cancer cases. Despite significant implications for survival, adherence to AET, which is prescribed as a daily oral tablet, is not optimal with the rate of nonadherence as high as 59% for tamoxifen and 50% for AIs in some studies 4 . The cost of non-adherence to AET is significant resulting in lost quality-adjusted life-years, increased medical costs, and increased mortality, highlighting the importance of developing adherence-promoting interventions for this fast-growing population 5 .
Breast cancer survivors have consistently reported that severe adverse events and side effects, or concerns of their development, are reported as a major barrier to discontinue AET [6] [7] [8] [9] [10] [11] [12] [13] . Common side effects of tamoxifen include gynecological symptoms such as vaginal bleeding and discharge 11 . AIs use may be accompanied by musculoskeletal problems (i.e., arthralgia and osteoporosis), cardiovascular effects, and sexual dysfunction 11, 14 . Both therapies are associated with an increase in vasomotor symptoms (i.e., hot flashes) and cognitive impairment 11 . Emerging quantitative studies have linked factors of cost, doctor-patient communication, health beliefs, fear of recurrence, self-efficacy, and lack of information and social support to intentional nonadherence 15, 16, 17, 18 . To date, qualitative studies in adherence research in patients taking oral anticancer drugs are emerging but still limited. Gaining an in-depth knowledge of the important factors that contribute to women's beliefs about the use or discontinuation of AET will allow us to develop intervention strategies promoting women's long-term adherence. Further, studies have reported that compared with other racial/ethnic groups, African American women have a higher rate of discontinuation of AET treatment, which might contribute to the differences in breast cancer mortality between African American and White women 1, 2, 21 . Thus, understanding African American women's unique experience and developing tailored strategies to enhance adherence to AET may help reduce disparities in breast cancer outcomes between African American and White women.
The goal of this qualitative study is to investigate women's barriers and facilitators to their adherence to AET and experiences with AET-related symptoms, and to explore any racial differences between Caucasian and African American women in their experiences and needs.
Methods

Sample
Participants were recruited from Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania, USA. Participants were women who had been diagnosed with primary breast cancer and had been prescribed Tamoxifen or AI between one and five years after primary treatment completion. Women taking endocrine therapy as part of treatment for metastatic disease were excluded, as this study focused on the perspectives of women taking AET to prevent recurrence. African American women were purposively sampled for the study. Sixteen women were approached and screened for the study; two ineligible, two with no interest, resulting in a total of six White and six African American women participating in the interview. Table 1 summarizes participant's demographic and medical characteristics (n=12). The mean age of participants was 52 years (range . The majority of the participants had some college (66.7%), reported an annual household income of more than $30,000 (58.4%), were unemployed (66.7%), were married (66.7%). Seven women were diagnosed either with stage II or stage III breast cancer (58%) and the majority completed chemotherapy (88.3%). Five women were prescribed Tamoxifen and seven were prescribed an AI daily. In average, women had been taking AET for two years. While taking AET, four women stated they never missed their AET tablets but seven reported they had occasionally missed their tablets. One women had stopped AET temporarily and another stopped permanently following her own volition.
Procedures
The study was approved by the FCCC Institutional Review Board. Recruitment of study participants occurred between June and December 2014. Women were recruited through clinician referral, study registry, and in person approach in medical oncology practices. Eligible women signed a consent form and completed a short demographic and medical characteristics survey before the interview. Interviews were conducted by the lead researcher (KYW) or the trained research coordinator (RS) in a private consultation room. Interviews lasted between 20 minutes and 1 hour. All participants received a $10 gift card for their time and effort.
Measure
The interviews were semi-structured and informed by topics from two recent review of factors associated with AET use 19, 20 . The interview guide was designed to probe topics on their understanding and expectations of AET, their experience with taking AET as prescribed, their experiences with AET-related side effects, and their suggestions on how to improve AET adherence and symptom management.
Analytic Strategies
Interviews were recorded, transcribed and checked for accuracy. Two phases of analysis were conducted. Initial coding was carried out using an a priori coding scheme based on the interview guide questions 21 . After the first round of coding, a research team group discussion was held to elicit new themes emerging from the data and to further refine the coding framework to include sub-themes that describe more concrete units of the higher-level themes. Themes and sub-themes were iteratively extracted, discussed, and agreed on by all research team members 22 .
Results
Analysis identified seven themes: 1) positive beliefs in AET; 2) uncertainty about long-term adherence; 3) experiences with side effects; 4) forgetting and remembering; 5) other concerns and information needs; 6) potential intervention format and 7) coping among African American women.
Theme 1: Positive Beliefs in AET
Reasons to take AET was greatly shaped by participants' perceptions and beliefs about the benefits of the therapy among this small group of women who adhered to AET.
For survival. Most women stated that they knew the therapy was important for their long-term survival, and that was the reason for taking their prescribed AET.
The oncologist explained to me the benefits long term of taking it, and that is why I continued to take it. [3- Coping with symptoms. Several women reported that their providers suggested they take the medication at night to avoid the symptoms. Women also reported using supplements to cope with symptoms. Long-term follow-up. While some women reported receiving information about AET from their providers at the time of treatment initiation, they also expressed that it was difficult to recall the information they had initially received, or it was too overwhelming to comprehend the information at the time. The possibility of a long-term follow-up to reiterate the importance of AET and potential new side effects was suggested. 
Discussion
The aim of this study was to explore and understand women's experiences and adherence behaviors after initiation of AET from 1 to 5 years. As found in other studies, most of the women interviewed in this study believed that taking the prescribed AET would improve their survival, despite the presence of side effects. This finding is consistent with the "necessity-concern" model 23 in that women who adhere to the therapy trusted and believed that the medication will prevent the recurrence of cancer, which to them was a motivation to adhere to the therapy although they had to tolerate significant side effects. The type and nature of AET-related side effects reported in the interviews were consistent with previous clinical reports in the literature 24, 25 . However, women reported receiving little support from their providers and the magnitude of symptoms sometimes strongly interfered with their daily activities. Further, providers might perceive side effects that affect the quality of life of patients taking AET are usually not life-threatening and differ from those that providers are mostly concerned about 26 . Therefore, AET-related symptom information might not be discussed with patients comprehensively. Unbiased and objective information about AET side-effects for patients is desired and critical. As the recommended duration of AET is being extended 27 , management of these symptoms is becoming increasingly important because these side effects can adversely impact both patient's quality of life and adherence to prescribed treatment. Future research needs to develop effective interventions to address a patient's doubt about the necessity for AET and concerns about side effects to enhance adherence.
Most women in our study believed that they were adherent and had implemented strategies in establishing a daily routine to help them remember to take their tablets. These routines generally consisted of a combination of keeping the medication somewhere they would be seen and/or taking the medication at a very specific time each day. Occasionally, forgetfulness usually occurred when the routine was not established yet (e.g., at the beginning of treatment initiation) or when the routine was interrupted (e.g., on vacation). Therefore, future research needs to inform initiation of care, where patterns of behaviors are established and carried out through the entire AET treatment regimen.
While patients of all ages may contend with challenges surrounding their treatment, younger women, who are interested in having biological children after treatment, face added complexity. Consistent with previous studies that younger women have questions regarding fertility 28 , our data suggest that some younger women might have unmet information needs about their fertility status during or after AET treatment. Interest in receiving fertilityrelated information was even identified among those who already have children at diagnosis, suggesting the importance of not overlooking the fertility issue among breast cancer patients with children. Clinicians need to be aware of and have an understanding for their younger patients' values regarding childbearing in order to assist them to make truly informed decisions and, thereby, adhere with their AET treatment.
Cancer patients often receive numerous medication, including anticancer drugs and drugs to treat comorbid conditions. These multiple treatments increase patient's uncertainty about drug interactions and any potential adverse effects, as suggested in our patient's responses.
Considering that a significant number of patients with hormone receptor-positive breast cancer would use AET treatment in the future, communication about the safety use of other drugs in relation to AET is an important part of survivorship care. Furthermore, our findings are also similar to those of previous studies that showed breast cancer patients desire information regarding nutrition and diet 29 . In particular, some of our participants expressed their strong desire to receive information about what to eat that would ease the AET-related side effects and improve their survival. Despite the availability of a range of resources and information sources that exist on the subjects of diet and nutrition in cancer, breast cancer patients continue to report unmet needs in the area of diet 30, 31 , perhaps indicating available information lacks specificity (e.g., in the context of AET). Our findings suggest an increase in provision of diet and nutrition information during AHT is needed.
Although previous interventions with patient educational materials and phone reminders have had minimal success in increasing AET adherence [32] [33] [34] , as some of our participants mentioned, future interventions should consider how to use technology (websites or text messaging or other "out-of-the-box" approaches) to promote AET adherence. Text messaging is one of the most accessible forms of mHealth communication, and evidence is emerging on the use of text messaging for a wide range of health and behavioral programs including medication adherence 35 . Text messaging might be an effective modality to promote AET adherence, as it can be integrated into women's daily life and adapted to individual needs in real time 36 . Using web-based or mobile platforms to offer medication reminders, symptom management, compliance comparison with the patient population, and survival rate improvements could be used to encourage women to comply with treatment recommendations. Future research should aim to quantify preferences for information tools and communication strategies in a larger sample with a focus on tailoring the interventions for women with different information needs and cultural ethnic background. Longitudinal interventions with longterm follow-ups at different time points to reiterate the importance of AET and strategies for managing new side effects would be also important, as updated guidelines recommend consideration of 10 years of AET in women with hormone receptor-positive breast cancer 27 .
Our findings suggest that religion and spirituality were important components in our African American women's breast cancer experience. Previous research showed that faith in God helped African American women cope during and after treatment, as they believed they could endure their treatment and related side effects and ultimately survive the disease 37, 38 . Further, the benefit of peercommunication was suggested in our African American subgroup. Therefore, future interventions targeting African American breast cancer women might want to consider utilizing spiritual ties or peer-led approaches for Our study was not without limitations. Our sample size was small and relatively well-educated, therefore, the views expressed by women in our study were not representative of the entire population of women receiving AET for their breast cancer. Future research should aim to extend our findings across a more diverse sample including different ethnic groups and low-literate populations. As identifying the cultural factors that contribute to ethnic variation in AET adherence is important, we also want to emphasize that individual patient's needs might be different, requiring personalized care and support. The majority of the women in our limited sample adhered to the AET so far, thus, findings from their experience might not be informative about non-adherence. Women who stopped AET completely were under-represented in this study (only one in our sample). It is possible that we were not able to reach non-adherent patients due to their loss for follow-up survivorship care or the lack of knowledge of their clinicians. Further qualitative studies targeting women who are known to be non-adherent would enhance the knowledge base in this area. Further, participants in this study were all recruited at a cancer center, thus participants were likely to respond to some doctor-patient relationship questions with socially desirable answers. The results obtained by the present study might be influenced by recollection bias. Prospective studies of women's AETrelated needs and how their experience change over time are critical.
Implications for patient-centered care practice
The findings from our study have several implications for patient-centered care practice 39 . First, for breast cancer patients making decisions to initiate and continue AET, information and communication from clinicians are important. Clinicians may encourage medication adherence by focusing on and communicating the value of the medication that the patient is taking, as well as providing complete and unbiased information about potential side effects. Second, clinicians need to listen to and respect patient's perspectives, concerns, and cultural beliefs about AET so that doctor-patient communication can be adjusted accordingly to positively influence patient medication adherence. Third, patients and families need to be encouraged with tools and resources to participate in decision-making about AET and in management of adherence behaviors and side effects through collaboration with clinicians. Taken together, our findings provide insight into the needs and experience of breast cancer survivors prescribed for AET. Although women in our study are generally highly compliant with their AET despite significant negative side effects, women's insights provide opportunities for targeted interventions to improve survivor's experience and symptom management, which could ultimately improve adherence, quality of life, and survival.
